Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term

分组1 - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [3][4] 分组2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E and Price/Sales, appealing to value investors [4] - The Growth Score assesses a company's future prospects through projected earnings and sales, targeting growth investors [5] - The Momentum Score evaluates price trends and earnings outlook changes to assist momentum investors in timing their purchases [6] 分组3 - The VGM Score combines all three Style Scores, providing a comprehensive rating that highlights stocks with attractive value, strong growth forecasts, and promising momentum [7] - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors in building successful portfolios [8][9] 分组4 - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [9] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] 分组5 - Theravance Biopharma (TBPH) is a biopharmaceutical company focused on respiratory medicines, currently rated 2 (Buy) with a VGM Score of A [12] - TBPH is projected to achieve year-over-year earnings growth of 175% for the current fiscal year, with upward revisions in earnings estimates [13]